Docket No.: 20747/200 (ARDW/P28269US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Jabbour et al.)	Examiner:
Serial No.		10/511,484)	David Lukton
3011011101	•	10,011,101	j –	Art Unit:
Cnfrm. No.	:	4407)	1654
Filed	:	October 21, 2005)	
For	:	FP RECEPTOR ANTAGONISTS OR PGF2 ALPHA ANTAGONISTS FOR TREATING MENORRHAGIA)))	

RESPONSE TO SUPPLEMENTAL RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS

Mail Stop: **Amendment** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the July 31, 2007, supplemental written restriction requirement, applicants hereby elect Group VI (i.e., claims 1-7) without traverse.

In response to the election of species requirements, applicants elect (a) administration of AL8810 by itself and (e) via administration to the female reproductive system. This mode of administration finds descriptive support at page 18, lines 7-8, of the application. Claims reading on the elected species include Claims 1-5.

Rejoinder of Group VII with elected Group VI, and examination of the claimed genus is respectfully requested.

Respectfully submitted,

Date: October 3, 2007 /Edwin V. Merkel/
Edwin V. Merkel
Registration No. 40,087

Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603 Telephone: (585) 263-1128 Facsimile: (585) 263-1600